VVOS — Vivos Therapeutics Balance Sheet
0.000.00%
- $7.16m
- $4.55m
- $13.80m
- 36
- 24
- 20
- 16
Annual balance sheet for Vivos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.469 | 18.2 | 24 | 3.52 | 1.64 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.956 | 1.52 | 1.2 | 0.457 | 0.202 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.98 | 20.4 | 27.3 | 5.42 | 2.46 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.14 | 0.872 | 2.83 | 4.78 | 4.7 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 7.55 | 25.3 | 33.7 | 13.7 | 10.7 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 9.09 | 7.82 | 7.51 | 6.81 | 7.29 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.18 | 8.41 | 8.15 | 8.92 | 10.3 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -1.63 | 16.9 | 25.5 | 4.8 | 0.411 |
Total Liabilities & Shareholders' Equity | 7.55 | 25.3 | 33.7 | 13.7 | 10.7 |
Total Common Shares Outstanding |